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Abstract

HEPATIC INSULIN RECEPTOR TYROSINE KINASE ACTIVITY IN
DIABETES: MODULATION BY ASSORTED ADENOSINE TRIPHOS¬
PHATASES/PHOSPHATASES WHICH COPURIFY IN PARTIALLY
PURIFIED PREPARATIONS OF THE INSULIN RECEPTOR. Darrick
J. Alaimo, Arthur I. Salhanick, and John M. Amatruda. EndocrineMetabolism Unit, Department of Internal Medicine, University of
Rochester School of Medicine and Dentistry, Rochester, New York.
(Sponsored by Robert Sherwin, Department of Internal Medicine, Yale
University School of Medicine).

We evaluated the assay conditions for quantifying insulin receptor
tyrosine kinase activation by insulin toward poly Glu/Tyr(4:l) in hepatic
plasma membrane and microsomal wheat-germ agglutinin eluates
prepared from normal and streptozotocin diabetic rats. Optimal insulin
receptor tyrosine kinase conditions were found to include HEPES buffer, the
absence of cytosine triphosphate, and the presence of sodium orthovanadate
(1 mM) and para-nitrophenylphosphate (10 mM). Using Lineweaver-Burke
analysis, the maximum insulin receptor tyrosine kinase activity was
demonstrated to be reduced by 43% (6.37 and 3.64 pmol 32p incorporated/
fmol insulin binding for control and diabetic preparations, respectively) in
plasma membranes and by 42% (6.80 and 3.97 pmol 32p incorporated/fmol
insulin binding for control and diabetic groups, respectively) in microsomes
from diabetic rats. Quantitation of 32p.orthophosphate generation during
incubations with [y32p]ATP revealed the presence of ATPase/phosphatase
activity that copurified with insulin receptors from wheat-germ agglutinin

columns. This activity was present in preparations from plasma mem¬
branes and microsomes and had a vanadate-insensitive component in
plasma membrane insulin receptor preparations. The decreased tyrosine
kinase activity found in preparations from diabetic rats cannot be explained
by this ATPase/phosphatase activity which was found to be lower (35-48%)
in diabetic preparations.
The results provide the first evidence that the insulin resistance of
nonketotic diabetes mellitus is associated with a reduction in hepatic
plasma membrane insulin receptor tyrosine kinase and describe the
presence of a copurifying ATPase/phosphatase activity. The mechanisms
underlying the decrease in insulin receptor kinase in diabetes and the
possible physiologic role for this copurifying ATPase/phosphatase activity
require further investigation.
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Introduction

The insulin receptor is a transmembrane glycoprotein composed of two
a-subunits and two P-subunits that are held together by disulfide bonds
(reviewed in 1). The a-subunits are highly glycosylated, extramembrane
peptides that bind insulin, while the P-subunits are glycosylated, trans¬
membrane peptides that have intrinsic tyrosine kinase activity (1). The
cloning of the insulin receptor gene has led to further definition of the
structure of the insulin receptor. The p-subunit has been found to contain a
tyrosine kinase domain that has a high degree of homology to other known
tyrosine kinases such as the src oncogene, the epidermal growth factor
(EGF) receptor, and the platelet-derived growth factor (PDGF) receptor
(reviewed in 2,3). The p-subunit also has an adenosine triphosphate (ATP)
binding region that appears to be necessary for tyrosine kinase activity (4,5).
The insulin receptor is responsible for mediating all of the biological
effects of insulin. Short-term effects occur within minutes and include
stimulation of nutrient uptake, glycolysis, glycogenesis, lipogenesis, and
inhibition of lipolysis and gluconeogenesis (reviewed in 5). Long term
effects occur over hours and include stimulation of cell growth, DNA
synthesis, and protein synthesis (5). Certain effects of insulin will pre¬
dominate in the cells of different organ systems (reviewed in 7). Liver and
muscle cells are highly responsive to insulin’s effects on gluconeogenesis,
glycogenesis, and nutrient uptake, while adipocytes are more responsive to
insulin's effects on lipolysis and lipogenesis.
The first step in insulin's action on a target cell is its binding to the asubunit of the insulin receptor (1). The signal is transduced by an
unknown mechanism, possibly by receptor clustering, that activates the
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tyrosine kinase domain of the (3-subunit (7). The (3-subunit autophosphorylates to a tri-phosphorylated form in the tyrosine-1150 domain which is
required for the tyrosine kinase to phosphorylate endogenous substrates
(2,9,10). Although the phosphorylation of numerous endogenous
uncharacterized proteins has been described (6,7,11,12,13), their relation to
intracellular signaling and insulin's actions remains to be elucidated.
By unknown means, intracellular signals activate a variety of
mechanisms which mediate the effects of insulin. For example,
enhancement of glucose transport is mediated by translocation of a glucose
transporter protein (glut-4) to the plasma membrane (PM) from
intracellular storage vesicles (6,14). Metabolic effects of insulin could be the
result of altering the activity of various kinases and phosphatases that are
involved in controlling the activity of regulatory enzymes of metabolism (6).
Another example of an intracellular effect of insulin is its effect on cell
growth which occurs via alterations in the rates of DNA replication and
transcription (6,7).
Many theories exist regarding the mechanisms by which insulin
binding results in intracellular signaling. Some theories revolve around
G-proteins (3,4). G-proteins are a group of intramembrane proteins that
are involved in coupling certain receptors to their second messenger
systems (i.e. (3-adrenergic receptors coupled to adenylate cyclase via the
G-protein, Gg). Although there are a number of different types of Gproteins, they all require the hydrolysis of guanosine triphosphate (GTP) for
signal transduction to occur (4). Houslay (3) has suggested that a unique
G-protein (Gins) is involved in insulin-stimulated inhibition of adenylate
cyclase because GTP is required.

He also has argued for Gins involvement

in insulin activated cyclic adenosine monophosphate (cAMP)
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phosphodiesterase (PDE) which requires GTP and can also be activated by
Cholera toxin, an activator of G-proteins. The insulin receptor tyrosine
kinase can phosphorylate G-protein subunits in vitro, and this ability could
be a mechanism of interaction (3). Further evidence has come from a study
(15) using streptozotocin-induced diabetic rats which showed that diabetic
liver tissue had a loss in both amount and activity of Gi (a different type of
G-protein) that was reversed by insulin administration. These results
suggested that insulin regulates the expression of Gi in the liver.

Because

Gi mediates inhibition of adenylate cyclase and may couple receptors to
potassium channels, decreased expression of Gi may be responsible in part
for some of the physiologic changes found in diabetes (15).
Some evidence has accumulated for a role for the calcium-calmodulin
second messenger system in the intracellular mechanism of action of
insulin.

In this second messenger system, an activated receptor system

increases intracellular calcium concentration.

Calcium then binds to the

protein calmodulin creating a complex which activates a number of
different calmodulin-sensitive enzymes (6). Calmodulin is phosphorylated
at a tyrosine residue in the calcium binding region by the activated insulin
receptor tyrosine kinase which could alter the activity of calmodulin (6).
Insulin enhances calmodulin binding to adipocyte plasma membranes
which may be related to the insulin-induced inhibition of a calmodulinsensitive adenosine triphosphatase (ATPase) found in plasma membranes
(2). There is evidence for calcium and calmodulin binding sites on the
(3-subunit of the insulin receptor, and these sites may be involved in
regulation of insulin receptor autophosphorylation (2).
Internalization of insulin bound to its receptor also seems to be
important in mediating the actions of insulin on various cellular processes.
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Internalization occurs either by the clathrin coated pit pathway (10%) or by
direct internalization via the non-coated pit pathway, and there are binding
sites for insulin on most organelles (2,7). Inhibition of insulin receptor
internalization and processing has been shown to inhibit a number of
effects of insulin including stimulation of glucose transport, regulation of
glycogen metabolism, and effects on RNA processing (2). Insulin and its
receptor have been localized in nuclear membranes where insulin has been
shown to activate a RNA-dependent nucleoside triphosphatase that
provides energy to transport large molecules through nucleopores (2).
Insulin may regulate messenger RNA efflux from the nucleus by this
mechanism and thus influence protein synthesis (2). However, by using a
mutated receptor, McClain has shown that the noninternalizing insulin
receptor is fully capable of activating glycogen synthetase and stimulating
mitosis in growth-arrested cells (16).
Other researchers have concentrated on the phosphatidylinositol
second messenger pathway while studying the intracellular mechanism of
action of insulin. In this second messenger system, an activated receptor
system stimulates a phospholipase which cleaves phosphatidylinositol, an
intramembrane phosphoglycolipid, to form inositol triphosphate and
diacylglycerol (DAG). Inositol triphosphate stimulates the release of
calcium from intracellular stores, while DAG activates Protein Kinase-C
(PK-C) (6). The insulin receptor tyrosine kinase has been shown to
stimulate phosphatidylinositol kinase, an enzyme involved in the synthesis
of phosphatidylinositol, via phosphorylation (6,11), but no changes in
inositol triphosphate or phosphatidylinositol levels have been found (6).
Insulin has been shown to stimulate DAG synthesis (2,14), but changes in
turnover have not been observed (2). Some studies have shown that insulin
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has no effect on PK-C activity (2), while a recent study by Cherqui et al. (14)
has provided evidence for myristoyl-DAG and PK-C involvement in insulinstimulated glucose uptake. Their study showed that cells transfected with
insulin receptor genes that were mutated at tyrosine residues 1162 and 1163
(major sites of autophosphorylation) had decreased tyrosine kinase activity
and 2-deoxyglucose uptake. In addition, the concentration-dose response
curves for insulin-stimulated myristoyl-DAG production and 2-deoxy¬
glucose uptake were superimposable in both normal and mutant cells.
They also showed that insulin-stimulated phosphorylation of a 40 kDa
protein (a known substrate for PK-C) was diminished in the mutant cells.
However, direct stimulation of PK-C could stimulate phosphorylation of the
40 kDa protein and uptake of 2-deoxyglucose in mutant cells to near control
levels. Thus, tyrosines 1162 and 1163 may control glucose uptake, at least in
part, via myristoyl-DAG production and PK-C activation.
Related to the phosphatidylinositol system are studies that have
concentrated on inositol phosphate glycans as mediators of insulin action.
Insulin has been shown to stimulate (possibly via a G-protein) a specific
phospholipase-C that liberates inositol phosphate glycans from PM
phosphoglycolipids (2,6,7,11). Phospholipase-C may also release DAG with
inositol phosphate glycans (6). Inositol phosphate glycans have been shown
to inhibit adenylate cyclase and to stimulate cAMP PDE and thus may be
involved in regulation of cAMP levels by insulin (6). These mediators are
also able to stimulate liver pyruvate dehydrogenase activity (6). Thus,
inositol phosphate glycans may be involved in some of insulin's actions.
However, some investigators have been unable to confirm the existence of
these mediators (6).

6

Although it is evident from the above discussion that multiple signaling
pathways are involved in insulin action, increasing evidence suggests that
the tyrosine kinase activity of the insulin receptor is involved in signal
transmission.

Insulin mimetic agents, such as concanavalin A, have been

shown to increase insulin receptor tyrosine kinase activity (1). Agents that
inhibit the insulin receptor tyrosine kinase have also been useful.
Catecholamines and phorbol esters were shown to inhibit insulinstimulated autophosphorylation, tyrosine kinase activity, and glucose
transport in isolated human adipocytes (17). Synthetic competitive
inhibitors of tyrosine kinases have been shown to inhibit insulin-stimulated
antilipolysis and lipogenesis (18).
Studies with antireceptor antibodies have been more equivocal.
Antibodies against the tyrosine kinase domain of the (3-subunit inhibit some
of insulin's actions (6), while a different antibody directed against the
(3-subunit has been shown to enhance insulin receptor tyrosine kinase
activity and to stimulate 2-deoxyglucose transport, lipogenesis, and
glycogen synthesis in isolated cells in a manner that was not additive to the
effect of insulin (19). Other antibodies against the a-subunit have been
shown to stimulate amino acid (20) and glucose (21) uptake in isolated cells
without stimulating insulin receptor autophosphorylation or tyrosine
kinase activity (20,21). These studies argued against an obligatory role for
the insulin receptor tyrosine kinase in the transmembrane signaling to
mediate all of insulin's actions. However, a study (4) using site-directed
mutagenesis showed that the replacement of lysine residue 1030 in the
putative ATP-binding domain of the insulin receptor abolished insulinstimulated autophosphorylation, tyrosine kinase activity, and
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2-deoxyglucose uptake. Interestingly, this mutation also prevented the
stimulation of 2-deoxyglucose uptake by various antireceptor antibodies that
had been previously shown to stimulate glucose uptake independent of
autophosphorylation or tyrosine kinase activity.
Further studies with site-directed mutations of the insulin receptor
have also suggested that the insulin receptor kinase is involved in
mediating many but not all of insulin’s actions. Studies using insulin
receptors mutated in the ATP-binding domain and thus deficient in kinase
activity have shown that the mutated cells also have impaired insulindependent 2-deoxyglucose uptake (4,5), S6 kinase activity, endogenous
substrate phosphorylation, glycogen synthesis, and DNA synthesis (5).
Site-directed mutation of tyrosine 960 did not affect autophosphorylation or
tyrosine kinase activity toward exogenous substrates but did inhibit insulinstimulated glycogen synthesis, amino acid uptake, DNA synthesis, and
phosphorylation of an endogenous substrate (pp 185) (22). This study
suggested that autophosphorylation was not sufficient to mediate some
actions of insulin and that tyrosine phosphorylation of cellular substrates
(which may involve tyrosine 960) was needed for signal transduction (22).
As discussed above, site-directed mutations at major sites of autophos¬
phorylation (tyrosines 1162 and 1163) result in diminshed tyrosine kinase
activity, but the decrease in 2-deoxyglucose uptake may be more related to
alterations in autophosphorylation, DAG production, and PK-C activity (14).
Furthermore, one study with insulin receptors mutated at the ATP-binding
domain showed that insulin-dependent stimulation of pyruvate
dehydrogenase bypasses the insulin receptor kinase (23).
Many genetic studies of patients with various clinical syndromes of
insulin resistance, including non-insulin-dependent diabetes mellitus
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(NIDDM), have added evidence that the insulin receptor kinase is involved
in signal transmission of insulin's actions. A number of studies on
patients with Type A extreme insulin resistance have shown that insulin
receptors from these patients have diminished autophosphorylation and
kinase activity but normal binding in vitro (12,24-28) and are often mutated
in the tyrosine kinase domain (12,25-28). Studies with these mutant
receptors in isolated cells have shown that some mutations result in the
inhibition of insulin-dependent phosphorylation of exogenous substrates
(pp 185) (12,27), 2-deoxyglucose uptake (28), DNA synthesis (12), or gene
expression (12). Yet, other mutations have no effect on insulin-stimulated
2-deoxyglucose uptake and glycogen synthesis (12). Thus, these and the
above mentioned studies suggest that the insulin receptor kinase is involved
in transmembrane signaling for many but not all of insulin's actions and
that a divergence of insulin signaling pathways seems to occur at the level
of the insulin receptor.
Many investigators have concentrated on quantitating insulin receptor
autophosphorylation and kinase activity in an attempt to gain insight into
the mechanisms responsible for various insulin resistant states, including
NIDDM. Some studies have concentrated on insulin resistant states
induced by obesity (13,29,30), fasting (31-33), hyperinsulinemia (34), or
catecholamines and phorbol esters (17), to examine the effects on insulin
receptor function, while others have focused on the insulin resistance of
NIDDM (10,13,30,33,35-51). Researchers have found decreases (10,13,17,
30,31,34,36,37,39-43,45-50), increases (29,30,33,51), or no change (29,32,35,38,
44,49) in autophosphorylation (10,13,17,29-33,36,38,39,41-44,46,48,49,51) and
tyrosine kinase (10,13,17,29-32,34-43,45-51) activities in insulin receptors
exposed to the above mentioned states of insulin resistance. Tissues from
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either insulin resistant humans (10,13,36,37,40, 45,47,50) or animals (17,
29-35,38,39,41-44,46,48,49,51) have been used in the studies. A majority of the
above studies have shown that decreases in insulin receptor autophospho¬
rylation and/or tyrosine kinase activity are present in insulin resistant
subjects. These observations suggest that a defect(s) at the level of signal
transmission is responsible for insulin resistance. However, as will be
discussed below, a number of differences in models and methodology may
make some studies less physiologically relevant.
While the transmembrane signaling mechanisms involved in insulin
action have been studied intensely, only recently have investigations
focused on the mechanism(s) by which the insulin receptor is deactivated.
Unlike many other receptors, the insulin receptor tyrosine kinase remains
active even after insulin dissociates from its binding site (11,52). The kinase
can be inactivated by phosphorylation of serine residues in the (3-subunit
(6,11). Phorbol esters and cAMP have been shown to stimulate serine
phosphorylation of the insulin receptor thus inhibiting the receptor kinase
(6,11). However, some studies have suggested that this mechanism of
receptor deactivation may be a mechanism of regulating insulin receptor
activity by other hormones (i.e. glucagon, catecholamines) rather than a
mechanism of terminating insulin's signal (6,17).
Many investigators have concentrated instead on the dephosphorylation
of autophosphorylation sites by phosphotyrosine protein phosphatases as a
mechanism of insulin receptor deactivation. A number of phosphotyrosine
phosphatases have been isolated that have activity against the autophosphorylated insulin receptor or similar phosphorylated peptides (9,52-59),
and some phosphatases can be stimulated by insulin (58,60,61). In
addition, other phosphotyrosine phosphatases have been isolated that
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possess activity against the phosphotyrosine forms of known exogenous
substrates of the insulin receptor tyrosine kinase such as histones (62,63),
casein (64,65), and poly Glu/Tyr(4:l) (54,66,67). Yet, no phosphatase activity
is intrinsic to the insulin receptor (56). Thus, phosphotyrosine phospha¬
tases may be involved in terminating insulin signal transduction at
different levels of the signaling pathway.
Despite the growing evidence supporting the importance of phospho¬
tyrosine phosphatases, only a few studies have addressed their role in the
hepatic insulin resistance of diabetes. The results of these studies are not
consistent, with reports of a decrease (55), increase (55), or no change (54) in
phosphatase activity of microsomal (54,55) or PM (54) preparations from
diabetic rats. In these studies, phosphatase activity was measured with an
artificial 32p-labelled substrate which may lack the sensitivity to highlyspecific phosphatases (e.g. phosphopeptide 1142-1153) (55) or may not be
representative of protein sequences (e.g. 32p_RCM-lysozyme) (54) of the
insulin receptor. The role of phosphotyrosine phosphatases in the patho¬
genesis of the insulin resistance of diabetes remains to be elucidated.
Previously, this laboratory has reported that autophosphorylation of the
hepatic insulin receptor of streptozotocin-diabetic rats (a model of NIDDM
in humans) was unaltered in partially-purified preparations extracted
from PM (44). This study was initiated because previous studies (33,43)
examined hepatic insulin receptor preparations made from microsomal
membranes which may not be physiologically relevant when considering
insulin action. Similarly, more recent studies (29,30,35,38,39,41,45,48,49)
examining insulin receptor autophosphorylation and tyrosine kinase
activity in diabetes have also used preparations not of PM origin. The
relevance of these investigations is also questionable, especially because a
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previous study from this laboratory (68) revealed that the contribution of PM
is only about 20 percent of the total cellular insulin binding in the hepatocyte. The present work establishes assay conditions and extends the
previous study (44) by evaluating hepatic insulin receptor kinase activity in
both PM and microsomal preparations from normal and streptozotocin
diabetic rats. In addition it describes the presence of copurifying ATPases
and phosphatase activities in these extracts
The type of buffer to be used in the study needs to be assessed during the
evaluation of assay conditions. The majority of the previously mentioned
studies have used either Tris (33,34,37,45,59,63,66,67) or HEPES (10,17,29,30,
32,36,39-44,46-53,55-57) as buffers. However, there is some evidence that
Tris-containing buffers may reduce insulin binding capacity (69,70), but the
ability of Tris to perturb insulin receptor kinase activity has not been
previously evaluated.
Another variable in previous studies that needs to be evaluated is the
use of cytosine triphosphate (CTP). A number of studies (31,35,36,38,40,
47,50,71-74) have used CTP as an inhibitor of adenosine triphosphatases
(ATPases) that may copurify with the insulin receptor and diminish the
apparent receptor kinase activity by limiting its substrate, ATP. CTP is
used because it does not compete with ATP at the insulin receptor kinase
(1) but is a good substrate for a number of broad specificity ATPases isolated
from hepatocyte membranes (75,76). When the effect of CTP on ATPase
activity has been evaluated, CTP has been effective in inhibiting ATPases in
most studies (36,38,50,71,74), but some investigators have found no effect
(31) or inconsistent effects (47) of CTP on ATPase activity. A 10:1 ratio (or
greater) of CTP:ATP concentrations should be sufficient for inhibition of
ATPases (76). Ratios of 10 or 20 are used in the majority of studies
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(31,36,40,50,71,72). In the present study, 2 mM CTP is used to give a
[CTP/ATP] ratio of 20:1.
The use of vanadate in previous studies has not been consistent and
warrants evaluation in the present study. Vanadate is a potent inhibitor of
many, but not all, phosphotyrosine phosphatases and ATPases (77,78) that
may copurify with insulin receptors purified on wheat germ agglutinin
columns (32,79,80). The majority of studies that have used vanadate and
evaluated its effect on phosphatase and/or ATPase activities have found it to
be effective (31,38,49,50,71,74), while others have found no inhibitory effect of
vanadate (33,36,47,79). Most investigators who have found vanadate to be
effective have used concentrations of 0.1 to 1.0 mM (31,38,49,50,74) which is
consistent with the fact that most phosphotyrosine phosphatases that have
been tested from rat liver are inhibited by 0.1 and 1.0 mM vanadate
concentrations (52-54,56,59). In the present work, 0.1 and 1.0 mM concen¬
trations are chosen to be evaluated.
The effectiveness of vanadate in inhibiting ATPases/phosphatases also
requires assessment. This ATPase/phosphatase activity can be detected by
measurement of 32p.0rthophosphate (32p^) generation during incubations
of insulin receptor preparations with [y32p] ATP. The molybdate technique
(81), which has been used in previous studies (38,43,74,82), is being used in
the present study because it allows the measurement of a large number of
samples taken from very small sample volumes. The data from the present
study show the presence of ATPase/phosphatase activity that copurifies
with the insulin receptor through lectin affinity chromatography.
In order to fully evaluate the activity of the insulin receptor tyrosine
kinase in these preparations it is necessary to assess activity when
substrate (ATP) conditions are not limiting. This evaluation can be
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accomplished by varying the ATP concentration and doing LineweaverBurke analysis to determine the maximum velocity (Vmax) and Michaelis
constant (Km) for the insulin receptor kinase (34). The data reveals that
microsomal and PM insulin receptors from diabetic rat livers have
decreased kinase activity compared to control rat hepatic insulin receptors.
Since the previous study from this laboratory (44) was performed at lower
ATP concentrations and in the absence of vanadate, the ATPase/
phosphatase activity detected in this work may explain the earlier finding of
normal kinase activity in insulin receptors prepared from PM of diabetic
rats. The results provide the first evidence that the insulin resistance of
nonketotic diabetes mellitus is associated with a reduction in insulin
receptor tyrosine kinase activity in hepatic PM.

.
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Methods

Reagents. Streptozotocin was a gift from The Upjohn Company
(Kalamazoo, MI); aprotinin, phenylmethylsulfonyl fluoride, poly Glu/Tyr
(4:1), bovine serum albumin (fraction V), sodium orthovanadate, and
unlabelled nucleotides were obtained from Sigma (St. Louis, MO); wheatgerm agglutinin-agarose (WGA) was from E-Y Laboratories (San Mateo,
CA); crystalline porcine insulin was a gift from Eli Lilly and Company
(Indianapolis, IN); [y32p]ATP (3000 Ci/mmol) was obtained from
Amersham Corporation (Chicago, IL); carrier-free [125j]Na was from New
England Nuclear (Boston, MA); Dextran T-500 was from Pharmacia-LKB
(Piscataway, NJ). All other chemicals were reagent grade.

Animals. Male-Sprague Dawley rats, approximately 2 months old and fed

ad libitum were used for all studies. Non-ketotic diabetes was induced by
the injection of streptozotocin (85mg/kg) via femoral vein as described
previously (83). Rats were used 2 to 4 weeks after injection and had elevated
serum glucose (>450 mg/dl) and low serum insulin (<8 |iU/ml).

PM Isolation and Lectin-Purification of the Hepatic Insulin Receptor.
Purified PM were isolated from 20 g of rat liver from normal and diabetic
rats as previously described (44,68). Marker enzyme profiles of these
preparations have been previously reported (68).

PM were extracted by

2-phase polymer method as previously described (68,84). Aqueous polymer
phases were prepared by mixing 30%(w/w) Polyethylene Glycol-6000 (PEG)
in H2O with 20%(w/w) Dextran-500 in H2O and 0.22 M phosphate buffer (pH
6.5), allowing to stand at 4°C for 48 hours, and then collecting the top and
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bottom phases separately. Liver homogenization was performed at 4°C in
the presence of 1 mM phenylmethylsulfonyl fluoride and 1.0 TIU/ml
aprotinin. The homogenate was centrifuged at 1200xg for 30 minutes, and
the pellet was saved and washed with 2 additional lOOOxg centrifugations
for 15 minutes each. The pellets were saved, suspended in top and bottom
phases, and centrifuged in a swinging bucket rotor at llOOxg for 15
minutes. PM were removed from the interface between the polymer phases
using a pasteur pipet, resuspended in top and bottom phases, and
centrifuged at llOOxg for 15 minutes. This collection and separation of PM
was repeated once more with the polymers, and then PM were washed in 50
mM Tris (pH 7.5) to dispel the polymers and spun at 2400xg for 10 minutes.
This Tris wash was repeated once, and then the pellets were then
resuspended in HEPES buffer, homogenized and stored at -70°C. PM
insulin receptors were extracted as previously described (68,84) except that
the final Triton X-100 concentration was increased from 1 to 2%(v/v). After
clarification of the detergent extract by centrifugation at 100,000xg for 60
minutes, the supernatant was diluted to 0.5%(v/v) Triton X-100 and recycled
three times through a WGA affinity column (44). After washing the
column with 50 mM HEPES buffer, pH 7.6, containing 150 mM NaCl, 10
mM MgS04, 0.02%(w/v) sodium azide, and 0.1%(v/v) Triton X-100, elution of
the insulin receptor was achieved by the inclusion of 300 mM N-acetyl-Dglucosamine in the above buffer. The protein content of column eluates was
determined by the dye-binding (Coomassie Blue) method of Bradford (85)
(Bio Rad Protein Assay) using bovine gamma globulin as the standard.
Aliquots were frozen at -70°C. The protein concentration of pooled fractions
was generally 0.8 to 1.4 mg/ml.
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Preparation of Microsomes. Microsomal membrane preparations were
prepared at 4°C from 20 grams of liver following homogenization in 50 mM
HEPES buffer, pH 7.6, containing 250 mM sucrose, 1 mM phenylmethylsulfonyl fluoride and 1 TIU/ml aprotinin. The homogenate was centrifuged
at 10,000xg for 20 minutes, the supernatant removed, and centrifuged at
100,000xg for 60 minutes. The pellet (microsomes) was saved, washed with
an additional 100,000xg centrifugation, and partially-purified on WGA
columns following solubilization in Triton X-100 as described above.

Insulin Binding ofWGA-Column Eluates. 125j_insuiin was prepared by
the Chloramine-T method as described by Cuatrecases (82). Prior to use,
the iodinated insulin was purified on a Bio-Gel P-30 column. Aliquots (5 to
15 pg of protein) of WGA column eluates were incubated with 125j_insuiin
(1 nM) in the presence and absence of 1 pM unlabelled insulin for 15 to 120
minutes at 24°C in phosphorylation buffer (see below), unless otherwise
noted. The incubation was terminated by placing on ice and adding bovine
gamma globulin and 10% PEG as previously described (68). Samples were
then centrifuged for 1 minute in a Beckman microfuge at 10,000xg. Pellets
were then washed with 10% PEG and counted in a gamma-counter.
Samples were run in quadruplicate, and data expressed in fmol insulin
bound/mg protein + standard deviation. For kinase and other assays, equal
binding for diabetic and control preparations was determined by varying
receptor protein concentrations at the same time of incubation, and then
the appropriate preparation was diluted with phosphorylation buffer.
Preliminary studies established that recovery of receptors with WGA
chromatography was comparable in liver extracts from control and diabetic
rats.
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Insulin Receptor Tyrosine Kinase Activity. Aliquots of lectin-purified PM
and microsomal insulin receptor preparations containing equal binding
activity (bound/total ranged from 10 to 15%) from normal and diabetic rats
were incubated at 24°C for 90 to 120 minutes in the absence and presence of
100 nM insulin in a buffer solution (total volume of 30 |il) modified from Zick
et al. (82). Except where noted, the phosphorylation buffer consisted of 50
mM HEPES buffer, pH 7.6, 50 mM NaCl, 20 raM MgCl2, 2 mM
Mn(CH3COO')2, 0.02%(w/v) bovine serum albumin, and 0.1%(v/v) Triton X100. Phosphorylation was initiated by the addition of a 10 pi solution
containing [y32p]ATP (final concentration 100 |iM), sodium orthovanadate
(final concentration 0, 0.1, or 1 mM), p-nitro-phenylphosphate (pNPP) (final
concentration 0 or 10 mM), and CTP (final concentration 0 or 2 mM). After
a 10 minute incubation at 24°C, 10 pi of phosphorylation buffer containing
poly Glu/Tyr (4:1) (final concentration was 1 mg/ml) were added (total
volume of 50 pi), and the incubation continued for an additional 5 to 20
minutes. The reaction was terminated with one-half volume of a "stopping
solution" (82) consisting of 50 mM HEPES buffer, pH 7.4, 40 mM NaH2P04,
20 mM EDTA-Na, 200 mM NaF, 40 mM sodium pyrophosphate, 40 mM
ATP, 20 mM pNPP, 5 mM sodium orthovanadate, and 0.4% Triton.
Aliquots were precipitated with tricholoracetic acid on Whatman 3MM
filter papers as described by Zick et al. (72). Filter papers were dried then
placed in cold 10% trichloroacetic acid (TCA) for 90 minutes. Filter papers
were then rinsed, and cold 10% TCA was replaced for 60 minutes. A third
10% TCA rinse of 15 minutes was performed, and then filter papers were
washed in 95% ETCH for 10 minutes. Filter papers were rinsed with
diethylether (reagent), dried, and then counted by liquid scintillation.
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Insulin dose response for tyrosine kinase activity was assessed by the above
procedure, but the insulin concentration was varied from 0 to 10"^ M.
Background subtractions were made by determining radioactivity on filters
prepared from incubations performed in the absence of insulin receptor
and/or poly Glu/Tyr(4:l). Kinase activity was expressed in pmol 32p
incorporated/fmol insulin-binding over 10 minutes of kinase incubation.
Samples were run in triplicate or quadruplicate.

Evaluation of Trichloroacetic Acid Wash Procedure. The TCA wash
procedure was used to precipitate the 32p_Giu.rpyr(4:i)j as described above.
The efficiency of the washes was evaluated in the following manner.
Control microsomal insulin receptors were incubated with [y32p]ATP for 10
minutes and then quenched with the "stopping solution" as described
above. Aliquots were spotted on filter papers and placed in 10% TCA. To
assess the stickiness of [y32p]ATP, blank filter papers were also placed in
the TCA. In wash procedure #1 washes were 90 minutes and then three 60
minute washes, while in wash procedure #2 washes were 90 minutes and
then three 15 minutes washes. Blank and sample filter papers were
withdrawn (in quadruplicate) and counted after each TCA wash. Data was
expressed as pmol 32p 0n filter paper/fmol of insulin bound.

Determination of Orthophosphate. 32p_orthophosphate content was
determined by the molybdate technique as described by Reinmann and
Umfleet (81). Aliquots from incubations were applied to Whatman 3MM
filter papers which were then placed in molybdate solution consisting of
1.5% TCA, 0.74% ammonium molybdate, and 7.4 mM triethylamine. Filter
papers were swirled occasionally for 10 minutes. Molybdate solution was
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then used to wash the filter papers for four more 10 minute periods. Filter
papers dried overnight and then were counted in a beta counter. Data was
expressed as either percent hydrolysis or pmol 32p_orthophosphate
formed/fmol insulin binding over 20 minutes of hydrolysis. Samples were
run in quadruplicate.

Lineiveaver-Burke Analysis. Insulin receptor tyrosine kinase activity was
assayed as discussed above except that the concentration of [y32p]ATP was
varied from 25 pM to 400 |iM. Data was expressed as above but was plotted
as a double reciprocal graph to allow Lineweaver-Burke analysis as
described in (29). Linear regression was performed in order to determine
maximum velocity (Vmax) and Michaelis constant (Km) for each set of
data.

Statistics. Statistical analyses were performed by using the non-paired
two-tailed Student's t Test.

Disclaimer. I performed all of the above methods with the exceptions of the
preparation of 125i_insuijn by the Chloramine-T method and the
determination of rat serum levels of glucose and insulin.
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Results

Insulin Binding ofWGA-Column Eluates. Partially-purified insulin
receptors from PM and microsomes isolated from control and
streptozotocin-diabetic rats were evaluated for insulin binding (tracer).
As shown in Figure 1, insulin binding to hepatic microsomal insulin
receptors from control and diabetic rats approached equilibrium between
60 and 90 minutes at 24°C which is similar to the results of other studies
performed at the same temperature (42,43,46). As reported by others
(30,39,41,43, 48,49), insulin binding was found to be higher (55-89%, 481±85
and 747+66 fmol insulin bound/mg protein for normal and diabetic prepara¬
tions respectively at 120 minutes incubation, p<0.05) (mean + standard
deviation) in WGA extracts from diabetic rat livers (Figure 1). This result
was in contrast with one study (35) which found decreased (by 50%) insulin
binding in alloxan-diabetic rat preparations. Previous studies (35,39,49)
have shown that these diabetes-induced changes in insulin binding are due
to alterations in receptor number and not receptor affinity.
Insulin binding in PM insulin receptors from control and diabetic
rats approached equilibrium in 60 to 90 minutes (Figure 2). This
equilibrium time was similar to that observed with microsomal prepara¬
tions at 24°C (Figure 1). Consistent with previous studies (38,44,45,51,68)
but in contrast to the results with microsomes, no difference in insulin
binding activity was found between control and diabetic PM insulin receptor
preparations, (261+104 and 285+118 fmol insulin bound/mg protein for
normal and diabetic preparations, respectively) (Figure 2). A previous
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Figure 1.

1251-INSULIN BINDING IN HEPATIC
MICROSOMAL INSULIN RECEPTORS

*

Figure 2.

125 I-INSULIN BINDING IN HEPATIC
PM INSULIN RECEPTORS

Figures 1.2.

125

I-insulin binding in hepatic insulin receptors.

Aliquots of lectin-purified hepatic microsomal (Figure 1) and
PM (Figure 2) insulin receptors from normal (open circles) and
diabetic (solid circles) rats were incubated with125I-insulin
(InM) in the presence and absence of unlabelled insulin ( }iM)
for 15 to 120 minutes in phosphorylation buffer as described in
Methods. The data represent the mean values from two to
four experiments each performed in quadruplicate. Statistical
comparisons between control and diabetic groups. * p<0.05.
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study (68) has also shown no difference in insulin binding affinity between
control and diabetic PM insulin receptors.

Evaluation of Trichloroacetic Acid Wash Procedure. Figure 3 shows that
the effectiveness of the washing of filter papers with TCA seemed to be more
dependent on the number of washes rather than on the duration of each
wash. Radioactivity on the filter papers with receptors reached a near
steady-state by the third wash of each wash procedure (Figure 3).
Presoaking the filter papers as described by Zick et al. (72) had no effect on
results (data not shown). Blank filter papers showed that the degree of
[y32p]ATP "stickiness" had also diminshed to a steady state by the third
wash and was a small percentage of the microsomal receptor activity (1418%) (Figure 3). For all subsequent experiments, a wash procedure of 90,
60, and 15 minute washes was employed.

Determination of Incubation Conditions for Insulin-Stimulated
Tyrosine Kinase Assay.

The effects of pNPP and vanadate on both insulin

binding and tyrosine kinase activity were assessed in control and diabetic
microsomal preparations initially equalized for binding in buffer lacking
these agents. As shown in Figure 4, pNPP (10 mM) and vanadate (0.1 and
1.0 mM) decreased insulin binding in microsomal insulin receptors by 20 to
29%. The relationship of insulin binding between diabetic and control
persisted in all three conditions. Because of this decrement in insulin
binding with pNPP and vanadate, later experiments involving these
inhibitors were conducted so that these inhibitors were added only with and
after the addition of [7^2p]ATP.
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EVALUATION OF TCA WASH PROCEDURE

Radioactivity on Filter Papers
(pmol 32 p on each disc/
fmol insulin bound)

Figure 3.

Figure 3. Evaluation of trichloroacetic acid wash procedure.
As described in Methods, filter paper discs contained radio¬
activity from microsomal insulin receptors incubated with
[y

32

P]ATP (solid circles and triangles) or from blank discs

(open circles and triangles). Discs were washed with four
successive washes according to procedure #1 (90 minutes then
60, 60, 60 minutes: circles) or procedure #2 (90 minutes then 15,
15, 15 minutes: triangles). Discs were removed in quadruplicate
after each wash and counted. The data represent mean values
from one experiment.
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Figure 4.

EFFECT OF pNPP AND VANADATE
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Figure 4. Effect of pNPP and vanadate on insulin binding.
Aliquots of hepatic microsomal insulin receptors equalized
125
for binding were incubated in
I-insulin in the absence
and presence of phosphorylation buffer containing 10 mM
pNPP and 0.1 and 1.0 mM vanadate. (B=kinase buffer
without inhibitors; PV-L, PV-H=kinase buffer with 10 mM
pNPP and 0.1 or 1.0 mM vanadate, respectively.) Data
represent mean values from one experiment performed in
quadruplicate.
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Preliminary experiments without pNPP or vanadate showed
minimal insulin-stimulated tyrosine kinase activity and a high degree of
variability in both microsomal and PM preps. As shown in Figure 5
(incubation time with poly Glu/Tyr[4:l]=10 minutes), the addition of pNPP
(10 mM) and vanadate (0.1 [PV-L] or 1.0 mM [PV-H]) to microsomal
preparations enhanced insulin-stimulated tyrosine kinase activity in the
control group (from 1.35+1.40 to 3.49±0.80 {+159%} or 3.60+1.14 {+167%} with
PV-L or PV-H, respectively pmol 32p incorporated/fmol insulin binding)
and in the diabetic group (from 1.73+0.91 to 2.02+0.30 {+17%} or 2.86+0.85
{+65%} with the addition of PV-L or PV-H, respectively). The relationship
between control and diabetic groups from microsomes was also altered with
the addition of vanadate and pNPP. Without inhibitors the diabetic kinase
activity was greater than the control (% Diabetic/Control [%D/C]= +28%),
whereas with inhibitors the opposite was true [%D/C= -42% (PV-L), -21%
(PV-H)].
As shown in Figure 6 (incubation time with poly Glu/Tyr[4:l]=10
minutes), the addition of pNPP and vanadate to PM insulin receptor
preparations enhanced insulin-stimulated tyrosine kinase activity. In the
control group, kinase activity increased from .09+.07 to 1.26+.56 or 1.45+.76
with PV-L or PV-H, respectively (pmol 32p incorpo- rated/fmol insulin
binding). Similarly, in the diabetic group kinase activity increased from
.01+.01 to 1.84+.88 or 1.63+.84 with PV-L or PV-H, respectively (same units
as above).

The effect of pNPP and vanadate on the variability of the data

was hard to assess because of the very low kinase activity without
inhibitors. The large increase in kinase activity with vanadate suggested a
high degree of contamination with ATPases/ phosphatases. The
relationship between control and diabetic groups of PM origin was also

.
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EFFECT OF pNPP AND VANADATE ON
INSULIN-STIMULATED TYROSINE KINASE
ACTIVITY IN MICROSOMES

Figure 5.
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ACTIVITY IN PM

< J
> w
3

■C

*

« 2
cs &

a I
.2 .9

I

CONTROL

DIABETIC

Figures 5.6. Effect of pNPP and vanadate on insulin stimulated tyrosine
kinase activity (AI) in microsomal (Figure 5) and PM (Figure 6) prepara¬
tions. Aliquots of lectin-purified hepatic microsomal and PM insulin
receptors from normal and diabetic rats were incubated in the presence
of 100 nM insulin, 100|JV1 [y 32 P]ATP, and phosphorylation buffer with
varying concentrations of pNPP and vanadate. (B=phosphorylation
buffer without inhibitors; PV-L, PV-H= kinase buffer with 10 mM pNPP
and 0.1 or 1.0 mM vanadate, respectively). Data represents mean values
two to four experiments performed in quadruplicate. Insulin-stimulated
tyrosine kinase activity (AI) was defined as kinase activity with insulin
minus kinase activity without insulin. Incubation time with poly
Glu/Tyr(4:l) was 10 minutes.
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altered with the addition of pNPP and vanadate. Without inhibitors both
diabetic and control insulin receptors exhibited very little insulinstimulated kinase activity, but the control had slightly more kinase activity
than the diabetic prep. With inhibitors the diabetic kinase activity was
greater than the control [%D/C= 1.84+.88/1.26+.56= +46%(PV-L); %D/C=
1.63±.84/1.45±.76= +12%(PV-H)], but there was a high degree of variability
which precluded statistical comparisons.

These increases in kinase

activity in diabetic PM is in contrast to the previous study by this laboratory
(44) in which insulin-sensitive insulin receptor autophosphory- lation was
unchanged in the diabetic, but in the PV-H group the diabetic and control
kinase activities were more similar than in the PV-L group.
The effect of Tris buffer on insulin-stimulated tyrosine kinase activity
in microsomal insulin receptors was measured in the presence of 0.1 mM
vanadate and 10 mM pNPP (incubation time with poly Glu/Tyr[4:l]=10
minutes). An initial experiment established insulin binding to be identical
when comparing activity in HEPES or Tris and to have no effect in the
insulin binding relationship of control and diabetic microsomal prepa¬
rations (data not shown). As shown in Table 1, Tris buffer reduced tyrosine
kinase activity in the control preparation by 36% (7.94 and 5.08 pmol 32p
incorporated/fmol insulin binding for HEPES and Tris buffers, respectively)
but had little effect on kinase activity in the diabetic preparation (4.00 and
4.13 for HEPES and Tris buffers, respectively in same units as above). The
relationship of less kinase activity in the diabetic preparation remained
intact although Tris decreased this difference. Because Tris buffer
selectively reduced insulin receptor kinase activity in the control
preparation, all subsequent experiments were conducted in HEPES buffer.
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Table 1.

Effects of Tris and HEPES Buffers on
Insulin-Stimulated Tyrosine Kinase Activity
in Microsomes
Tyrosine Kinase Activity (AI)
(pmol 32 P incorp/fmol insulin bound.)

BUFFER

CONTROL

DIABETIC

ft. D/C

Hepes

7.94

4.00

-50%

Tris

5.08

4.13

-19%

% change
due to Tris

-36%

+3%

Table 1. Effects of Tris and HEPES buffers on insulin-stimulated tyrosine
kinase activity in microsomes. Aliquots of lectin-purified hepatic micro¬
somal insulin receptors from control and diabetic rats were incubated in
the presence of 100 nM insulin, poly Glu/Tyr(4:l)(incubation time=10
minutes), 100 pM ATP, 10 mM pNPP, 0.1 mM vanadate, and phosphorylation
buffer made with either Tris or HEPES. The data represent the mean
values from one experiment performed in quadruplicate.

Table 2.

Effect of CTP on Insulin-Stimulated
Tyrosine Kinase Activity in Microsomes

Tyrosine Kinase Activity (AI)
(pmol 32 P incorp/fmol insulin bound).

CTP

CONTROL

DIABETIC

0 mM

3.12

1.75

44%

2 mM

0.89

0.55

-38%

-71%

-69%

% change
due to CTP

%D/C

Table 2. Effect of CTP on insulin-stimulated tyrosine kinase activity in
microsomes. Aliquots of lectin-purified hepatic microsomal insulin
receptors from control and diabetic rats were incubated in the presence of
100 nM insulin, poly Glu/Tyr(4:l)(incubation time=10 minutes), IOQjM ATP,
10 mM pNPP, 0.1 mM vanadate, and CTP (0 or 2 mM). The data represent
the mean values from one experiment performed in quadruplicate.
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The effect of CTP on insulin-stimulated tyrosine kinase activity was
investigated using hepatic microsomal insulin receptors isolated from
control and diabetic rats. Insulin receptors were incubated in the presence
of 0.1 mM vanadate and 10 mM pNPP (incubation time with poly
Glu/Tyr[4:l]=10 minutes). Table 2 shows that the addition of CTP (2mM)
resulted in a similar decrease (ca. 70%) in insulin-stimulated kinase
activity in the control and diabetic preparations. This result is in contrast
to previous studies in which CTP enhanced insulin receptor tyrosine kinase
activity (36,38,50,71,74) or had no effect on tyrosine kinase activity (31).
Although the relationship between diabetic and control kinase activities
(%D/C= -44%) was preserved in the presence of CTP (%B/C with CTP= 38%), CTP was omitted in subsequent experiments because of the negative
influence on both diabetic and control receptor activities.

Evaluation of the Time Course of Insulin Receptor Tyrosine
Kinase Activation. Experiments were performed in the absence or
presence of 1.0 mM vanadate and 10 mM pNPP (PV-H). Incubation time
with poly Glu/Tyr(4:l) was varied from 5 to 20 minutes in order to evaluate
the time course of microsomal and PM insulin receptor kinase activity
isolated from control and diabetic rats. In microsomal hepatic insulin
receptors without vanadate and pNPP, the control group kinase activity
approaches equilibrium (5-10 minutes) before the diabetic group kinase
activity (10-20 minutes) (Figure 7). However, when vanadate and pNPP
were added to the reaction mixture, activation of both control and diabetic
receptor kinases was nearly linear for up to 20 minutes. All other
experiments with microsomes were incubated with poly Glu/Tyr(4:l) for 10
minutes in order to make linear measurements of tyrosine kinase activity.
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Figure 7.
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Figure 7. Time course of insulin-stimulated tyrosine kinase activity
in microsomal preparations. Aliquots of lectin-purified hepatic
microsomal insulin receptors from normal (open circles and triangles)
and diabetic (solid circles and triangles) rats were incubated in the
32
presence of 100 nM insulin, 100 |M [7
P]ATP, and phosphorylation
buffer without (circles) or with (triangles) pNPP (10 mM) and vanadate
(1 mM). Incubation time with poly Glu/Tyr(4:l) was varied from 5 to 20
minutes. Data represent the mean from two experiments performed in
quadruplicate.
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This incubation time was shorter in comparison to those used in previous
studies conducted at 24°C (31,34,37,38,46). In one study conducted without
vanadate, incubation time was 20 minutes (34), but those studies done in the
presence of vanadate used incubations of 15 to 30 minutes (31,37,38,46).
Interestingly, one study (30) that was conducted at 4°C with vanadate
showed that microsomal insulin receptor tyrosine kinase activity was
linear with respect to time for up to 120 minutes.
Diabetic microsomal receptor kinase activity was less than control
activity at all time points to a similar degree (%D/C= -16% to -40%) when
incubated with vanadate and pNPP. In their absence, control kinase
activity was greater than diabetic activity at 5 minutes but had become less
than diabetic activity at 20 minutes. These results thus suggest the
presence of a greater degree of ATPase/phosphatase activity (causing [ATP]
to become more limiting with time) in the control preparation.
In PM, the time course of insulin receptor tyrosine kinase activation
could only be assessed in the presence of vanadate and pNPP because poor
insulin responses were observed without inhibitors. As shown in Figure 8,
kinase activation in both control and diabetic insulin receptors remained
nearly linear with respect to time through 10 minutes of incubation.
However, by 20 minutes both control and diabetic activities had plateaued.
The former plateaued sooner and at a lower kinase activity which
suggested that [ATP] was becoming limiting or dephosphorylation was
occurring and to a larger degree in the control preparation. Consequently,
an incubation time of 10 minutes was chosen for all other experiments with
PM.

Evaluation of the Effect of Insulin Concentration on Insulin
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Figure 8.

TIME COURSE OF INSULIN RECEPTOR
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Figure 8. Time course of insulin-stimulated tyrosine kinase
activity in PM preparations. Aliquots of lectin-purified
hepatic PM insulin receptors from normal (open circles) and
diabetic (solid circles) rats were incubated in the presence of
32
100 nM insulin, 100
[y
P]ATP, and phosphorylation
buffer with pNPP (10 mM) and vanadate (1 mM). Incubation
time with poly Glu/Tyr(4:l) was varied from 5 to 20 minutes.
Data represent the mean values from two experiments
performed in quadruplicate.
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Receptor Tyrosine Kinase Activity. The effect of insulin concentration on
tyrosine kinase activity was evaluated in both microsomal and PM insulin
receptors in the presence of 0.1 mM vanadate and 10 mM pNPP as
described in Methods. As shown in Figures 9 and 10, microsomal and PM
insulin receptor kinases were activated at both physiologic (0.1 and 1.0 nM)
and pharmacologic (10 and 100 nM) insulin concentrations. Physiologic
and pharmacologic concentrations of insulin have previously been shown to
stimulate the insulin receptor tyrosine kinase in intact hepatocytes (80).
Figure 9 shows that the dose response curves for control and diabetic
microsomal receptor kinase activities were almost identical in shape.
Diabetic and control kinase activities were similar at all insulin
concentrations in this preparation.
As shown in Figure 10, the dose response curves for control and
diabetic PM receptor kinase activities were similar in shape. However, for
this particular preparation, the diabetic receptor kinase activity was
greater than the control receptor kinase activity at all concentrations of
insulin tested (%D/C= +36 to +64% for [insulin] > 1.0 nM).

32p-Orthophosphate Formation in Insulin Receptor Preparations.
In view of studies demonstrating changes in the membrane concentration
of ion-pump ATPases in diabetes (88,89), the extent of 32p-0rthophosphate
generation was measured concomittant with measurements of poly
Glu/Tyr(4:l) phosphorylation, as described above. The results of these
experiments with microsomal and PM preparations are shown in Figures
11 and 12, respectively. In the absence of vanadate and pNPP, the amount
of 32p-iabelled orthophosphate formed (pmol/fmol insulin binding/20 min)
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Figure 9.

EFFECT OF [INSULIN] ON INSULIN RECEPTOR
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EFFECT OF [INSULIN] ON INSULIN RECEPTOR
TYROSINE KINASE ACTIVITY IN PM

Figures 9.10. Effect of insulin concentration on insulin receptor
tyrosine kinase activity in microsomal (Figure 9) and PM (Figure 10)
preparations. As described in Methods, aliquots of lectin-purified
hepatic microsomal and PM insulin receptors from normal (open
circles) and diabetic (solid circles) rats were incubated in the presence
of [y 32 P]ATP (100 |jM), pNPP (10 mM), vanadate (O.lmM), and varying
concentrations of insulin (0 to 100 nM). Basal tyrosine kinase activity
in microsomes was 0.76 (control) and 0.81 (diabetic) (pmol32 P
incorporated/fmol insulin bound), while it was 0.99 in control and
1.05 in diabetic from PM preparations. Data represent the mean
values from one (microsomal) or four replicate (PM) experiments
performed in quadruplicate.
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was 74 (9.0% hydrolysis) and 45 (5.1% hydrolysis) in insulin receptor
preparations from microsomes of normal and diabetic rats, respectively
(Figure 11) and was 313 (23% hydrolysis) and 247 (18% hydrolysis) in insulin
receptor preparations from PM of normal and diabetic rats, respectively
(Figure 12). In the presence of the vanadate and pNPP, an 88% decrease in
32p-orthophosphate levels was found in control microsomal insulin
receptor preparations (Figure 11: decreased to 8.9 [1.1% hydrolysis]), while
an 87% decrease was seen in diabetic microsomal insulin receptor prepa¬
rations (Figure 11: decreased to 5.8% [0.7% hydrolysis]). In contrast, the
addition of vanadate to insulin receptor preparations from PM resulted in
decreases of only 41% in preparations from normal (Figure 12: decreased to
185 [14% hydrolysis]) and 61% in preparations from diabetic (Figure 12:
decreased to 96 [7.1% hydrolysis]) rats.
The generation of 32p.orthophosphate was less in the diabetic
preparation than in the control preparation for each set of experimental
conditions.

In the microsomal insulin receptor preparations, the level of

32p-orthophosphate formation was 39% or 35% less in the diabetic group
than in the control group when incubated in the absence or presence of
vanadate and pNPP, respectively. Similarly, in the PM insulin receptor
preparations, the diabetic group exhibited 21% less 32p_0rthophosphate
formation than the control group in the absence of vanadate and 48% less
than the control group in the presence of vanadate.
These results suggested that ATPase and/or phosphatase activity
was present in all preparations of insulin receptors tested. This activity
was 4 to 21 times greater at all experimental conditions in preparations of
PM origin than in preparations from microsomes.

Furthermore, vanadate

inhibited this ATPase and/or phosphatase activity but to a greater extent in
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Figure 11.

32P-ORTHOPHOSPHATE FORMATION IN INSULIN
RECEPTOR PREPARATIONS FROM MICROSOMES
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32 P-ORTHOPHOSPHATE FORMATION IN INSULIN
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and pNPP
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and pNPP

DIABETIC

Figures 11.12.
P-orthophosphate formation in insulin receptor
preparations. Aliquots of lectin-purified hepatic microsomal (Figure
11) and PM (Figure 12) insulin receptors from control and diabetic
rats were incubated in the presence of 100 jjM [y32 P]ATP, 100 nM
insulin, poly Glu/Tyr(4:l), and kinase buffer without (B) or with pNPP
(10 mM) and vanadate^l mM). Samples from aliquots were sub¬
sequently assayed for z P-orthophosphate content as described in
Methods (20 minutes of hydrolysis). Data represent the mean values
from two experiments performed in quadruplicate.
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insulin receptor preparations from microsomes than in those from PM.
These ATPases and/or phosphatases were also found to be less active in
comparable preparations from diabetic rats than those from normal rats.

Determination of the Effect of ATP Concentration on Insulin Receptor
Tyrosine Kinase Activity.

In order to assess the activity of the insulin

receptor tyrosine kinase without the confounding factor of copurifying
ATPase/phosphatase activity, tyrosine kinase activity was evaluated when
at multiple ATP concentrations. These experiments were conducted by
varying the ATP concentrations (25 to 400 pM) and using double reciprocal
plots (Lineweaver-Burke) for analysis of tyrosine kinase activity in order to
determine the Vmax and Km for the insulin receptor kinase from normal
and diabetic preparations in the presence of 1 mM vanadate and 10 mM
pNPP as described above. As shown in Figures 13 and 14, the Vmax was
reduced by 42% in the diabetic preparation from microsomes (Figure 13:
6.80 and 3.97 pmol 32p incorporated/fmol insulin binding for control and
diabetic preparations, respectively) and by 43% in the diabetic group from
PM (Figure 14: 6.37 and 3.64 pmol 32p incorporated/fmol insulin binding
for control and diabetic preparations, respectively). The relationship of
greater kinase activity in the control group remains intact at all ATP
concentrations tested in microsomal preparations, but in PM preparations
this relationship inverts at ATP concentrations less than about 150 pM.
These ATPase/phosphatase activities were also consistent with an
observed diabetic Km (Figure 14: 45 pM ATP) which is 76% less than the
control Km (Figure 14: 190 pM ATP) in PM preparations. Higher ATPase/
phosphatase activity in the control group would increase the Km- In
microsomes where the ATPase/phosphatase activities are not so disparate,
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EFFECT OF [ATP] ON INSULIN RECEPTOR
TYROSINE KINASE ACTIVITY FROM
MICROSOMES

Figure 13.
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Figures 13.14. The effect of ATP concentration on insulin receptor
tyrosine kinase activity in PM and microsome preparations.
Aliquots of lectin-purified hepatic PM and microsomal insulin
receptors from control (open circles) and diabetic (solid circles)
rats were incubated in the presence of 100 nM insulin, 25 to 400 pM
[y 32p]ATP, and poly Glu/Tyr(4:l) as described in Methods. The
data are expressed in double reciprocal plots and represent the
mean values from one experiment performed in quadruplicate.
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the diabetic Km was still 35% less than the control (Figure 14: 36 and 55 pM
ATP in diabetic and control preparations, respectively). These results are
consistent with previous studies in which the Km of ATP for the insulin
receptor tyrosine kinase was found to range from 30 to 150 pM ATP
(reviewed in 8).

.

40

Discussion

A major interest of this laboratory has been to explore the
mechanisms underlying hepatic insulin resistance.

With regard to the

insulin resistance of nonketotic diabetes mellitus, this laboratory has
previously reported (44) that PM insulin receptor autophosphorylation in
response to insulin was normal in streptozotocin-induced diabetic rat
livers. It was concluded that the hepatic insulin resistance of nonketotic
diabetes mellitus resides distal to insulin receptor binding and autophos¬
phorylation. The present study extended the earlier work by this laboratory
(44) by examining the tyrosine kinase activity (toward poly Glu/Tyr[4:l]) of
hepatic insulin receptors prepared from the PM of normal and streptozotocin-diabetic rats.

For comparison, insulin receptors were prepared

from hepatic microsomes and were analyzed.
Experiments testing insulin binding were conducted in order to
equalize binding between control and diabetic insulin receptor preparations
and to confirm previous observations of insulin binding in microsomes and
PM.

The finding of increased binding in microsomal insulin receptors

isolated from diabetic rats (Figure 1) was consistent with the results of
earlier studies (30,39,41,43 48,49). In contrast, one study using a different
rat model of diabetes did find reduced insulin binding in diabetic micro¬
somal receptors (35). Experiments with PM preparations (Figure 2)
revealed no difference in insulin binding activity between control and
diabetic receptors and confirmed the observations made by this laboratory
(44) and other investigators (38,45,51,68). It is unclear why microsomal
insulin binding increases in diabetes while PM insulin binding remains
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unchanged.

Perhaps insulin receptor degradation decreases in diabetes

leading to receptor accumulation in the microsomal compartment.
Experiments were performed to evaluate the effect of insulin
concentration on insulin receptor tyrosine kinase activity (Figures 9,10).
Because receptor kinase activity was enhanced at all insulin concentrations
tested (0.1 to 100 nM), results from the present study that were obtained
using 100 nM insulin were the result of a true insulin effect rather than the
early stage of a growth factor effect which occurs at insulin concentrations
of greater than 1000 nM (6).
Initial experiments measuring tyrosine kinase activity revealed a
high degree of variability. The trichloroacetic acid wash procedure was
evaluated in order to eliminate the washing of filter papers as a possible
source of this variability. TCA washing was found to be quite effective in
bringing radioactivity on filter papers to a steady state within three washes
while minimizing the degree of [y32p]ATP "stickiness" (Figure 3). Thus, it
is unlikely that inefficient TCA washing of filter papers accounted for the
variability seen in the tyrosine kinase assay.
In addition to the variability observed in the assay, insulinstimulated tyrosine kinase activity in PM receptors was minimal in initial
experiments. The type of buffer was investigated as a possible source of this
blunting of kinase activity. Tris buffer had no direct effect on insulin
binding but did seem to inhibit kinase activity in microsomal insulin
receptors (Table 1). So, in addition to Tris affecting insulin receptor
recycling in intact cells (69,70), the current results show a direct inhibitory
effect on insulin receptor tyrosine kinase activity. The mechanism
underlying this inhibitory effect of Tris is unclear at the present time.
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Just as initial tyrosine kinase results were variable in the present
study, the literature is filled with inconsistencies with regard to hepatic
insulin receptor tyrosine kinase measurements. Previous investigations
examining hepatic insulin receptor tyrosine kinase in diabetes have pointed
towards alterations, but the results have been contradictory (29,30,33,35,38,
39,41,43-45,48,49). If the methodologies used in these studies are compared,
one observes that in all (30,39,45,48,49) but one study (44) receptor tyrosine
kinase activity was reduced in the diabetic groups when insulin receptor
preparations were incubated with [y32p]ATP at 4°C. In contrast, when
insulin receptor preparations were incubated at ambient temperatures (2024°C) and in the absence of vanadate, a majority of studies (29,35,49)
demonstrated no change or even enhanced receptor tyrosine kinase activity
in diabetic preparations. In a study examining tyrosine kinase activity
(toward angiotensin-I) in insulin receptor preparations made from rat
skeletal muscle, Burant et al. (42) described reduced activity in diabetic
preparations at incubation temperatures of 25° and 4°C with insulinagarose bound (purified) and non-immobilized (partially purified) insulin
receptors, respectively. This finding would suggest that the observed
inconsistencies between phosphorylation studies performed at 4°C (30,39,
45,48,49) and 20-24°C (29,35,49) could have been the result of "contami¬
nating" activities (ATPases/ phosphatases?) which are active at ambient
temperatures. These activities are apparently absent in more highly
purified preparations of the insulin receptor (43,56,74,79).
CTP has been employed as a competitive inhibitor of contaminating
ATPases (31,36,38,50,71,74). In the majority of these studies (36,38,50,71,74),
the addition of CTP led to enhanced insulin receptor tyrosine kinase
activity. In light of these results CTP was added to the tyrosine kinase
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reaction mixture in an attempt to eliminate variability and enhance the
minimal insulin response by inhibiting ATPases that might be copurifying
with the insulin receptor. Unexpectedly, CTP actually reduced insulinstimulated tyrosine kinase activity in both control and diabetic preparations
(Table 2). The mechanism of this effect was not further investigated, but
since CTP has not been shown previously to inhibit the insulin receptor
tyrosine kinase, a direct effect is unlikely.
A number of studies have used vanadate in an attempt to inhibit
contaminating phosphotyrosine phosphatases and ATPases (31,33,36,38,
47,49,50,71,74,79). A majority of studies (31,38,49,50,71,74) found vanadate to
be effective in this role, so the effect of vanadate was evaluated in the
present study. Vanadate was shown to enhance insulin-stimulated
tyrosine kinase activity in both microsomal (Figure 5) and PM (Figure 6)
preparations suggesting the presence of ATPases/phosphatases sensitive to
vanadate.

In microsomes, vanadate actually enhanced tyrosine kinase

activity to a greater extent in control preparations than in diabetic
preparations suggesting more ATPase/phosphatase activity copurified with
the control group.
Experiments that examined the time course of insulin-stimulated
tyrosine kinase activity with and without vanadate yielded similar results.
In microsomes without vanadate (Figure 7), kinase activity plateaued
earlier in the control than in the diabetic group, but when vanadate was
added kinase activity was nearly linear for up to 20 minutes in both groups.
These findings suggested again the presence of vanadate-sensitive
ATPases/phosphatases in microsomal preparations with more activity in
the control group. In PM preparations, in the presence of vanadate
insulin-stimulated kinase activity was nearly linear over the first 10

44

minutes of incubation but plateaued in control preparations by 20 minutes,
again implicating more ATPase/phosphatase activity or a greater
vanadate-insensitive component in the control group.
With the previous experiments implicating the presence of
contaminating ATPases/phosphatases, the actual combined activities of
these enzymes were assessed by measuring their by-product, 32p_
orthophosphate (from the hydrolysis of [y32p]ATP by ATPases or from
dephosphorylation of ^^P-labelled. insulin receptor by phosphatases). These
data confirmed the existence of contaminating ATPases/phosphatases in
both microsomal (Figure 11) and PM (Figure 12) preparations. ATPase/
phosphatase activities were found to be greater in control than in diabetic
preparations from both membrane compartments. This activity was also
significantly inhibited by vanadate in all preparations, however to a lesser
degree in the PM preparations, suggesting a vanadate-insensitive
component.
In a continuation of the present study, this laboratory evaluated
dephosphorylation of 32p_iakeiied (3-subunits of the insulin receptor and
found this activity to be higher in insulin receptor preparations from
control PM compared to diabetic PM (90). This result is in contrast to
previous studies in which microsomal phosphatase activity was found to be
unchanged (54) or increased (55) by diabetes. A residual vanadateinsensitive phosphatase was also detected, and preliminary
characterization showed it to be a phosphotyrosine phosphatase (90).
Previous studies that have isolated phosphatases capable of dephosphorylating the phosphorylated forms of the insulin receptor (52-57,59) or poly
Glu/Tyr(4:l) (64,67) have shown this activity to be inhibited by vanadate at
doses (1 mM) equal to or less than that used in the present and following
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(90) studies. However, vanadate-insensitive phosphotyrosine phosphatases
have been isolated (77,78). The function of the phosphatases and ATPases
present in the current study and their alterations in diabetes merit further
investigation.
The extent of ATPase/phosphatase contamination found in insulin
receptor preparations from microsomes appears to be determined by the
amount of protein used in incubations to measure insulin receptor tyrosine
kinase activity. For example, in microsomes (Figure 11) the ATPase/
phosphatase activity based on 32p.orthophosphate formation per unit
insulin binding is 64% higher in the control than in the diabetic prepa¬
rations but only 30% higher based on activity per unit protein. This finding
may explain the observation of Kadowaki et al. (43) who reported ATP
hydrolysis to be higher (12.5% compared to 4.5% at 4°C) in microsomal
insulin receptor preparations from control rats compared to those from
diabetic rats. The fact that ATPase/phosphatase activity seems to vary with
protein content stresses the importance of monitoring this copurifying
activity when comparing preparations of equal binding but different protein
content (e.g. microsomal preparations).
Insulin receptor tyrosine kinase activity was examined when ATP
concentration was not limiting and in the presence of vanadate in order to
eliminate the effect of copurifying ATPases/phosphatases.

In microsomal

preparations (Figure 13), double reciprocal plot analysis of the data revealed
a Vmax for the diabetic group which was 42% less than that of the control
group in agreement with a continuation of the present study by this
laboratory (56% reduction in the diabetic Vmax) (90). This finding of
reduced tyrosine kinase activity in the diabetic group confirmed the results
of a majority of previous studies evaluating tyrosine kinase activity at sub-

46

maximal (11,30,32,34, 39,41,43,45,48,49) and maximal (11,32,34) ATP
concentrations.
Double reciprocal plot analysis of data from PM preparations (Figure
14) found a Vmax for the diabetic group which was 43% less than that of the
control group. This finding was in agreement with the continuation of the
present study by this laboratory (38% reduction in diabetic Vmax) (90) but
was in contrast to the previous study by this laboratory (44) which found
that diabetes did not affect insulin-stimulated insulin receptor autophos¬
phorylation. A possible explanation is that autophosphorylation and
phosphorylation of other substrates are uncoupled in diabetes. On the other
hand, this discrepancy might be explained by the intersecting lines of the
double reciprocal plot (Figure 14). In the presence of the lowest concen¬
tration of ATP tested (25 pM), the insulin-sensitive tyrosine kinase activity
was found to be 77% higher in insulin receptor preparations from diabetic
rats, whereas at Vmax, tyrosine kinase activity was 43% lower in the
diabetic group. The greater vanadate-insensitive ATPase activity observed
in the control preparation (discussed above, Figure 12) probably contributed
greatly to these observations. At low ATP concentrations, the disparate
ATPase/phosphatase activities would reduce the measurable kinase activity
significantly more in the control than in the diabetic preparations so that
the diabetic kinase activity would seem greater than or equal to the control
activity. At high ATP concentrations, the effect of ATPase/phosphatase
activity would be relatively insignificant, and the true kinase activities of
the insulin receptors would be observed.
In light of these findings, the ATPases/phosphatases present in PM
preparations but not completely inhibited by vanadate probably confounded
the earlier experiments (Figure 6) conducted at submaximal ATP (100 pM)
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in which it was concluded that PM tyrosine kinase activity is higher in the
diabetic group. Similarly, these ATPases/phosphatases probably also
confounded the results of the previous study by this laboratory (44) because
it was conducted in the presence of only 25 pM [y32p]ATP and in the
absence of vanadate. In fact, when this experiment was repeated by this
laboratory in the presence of 100 pM fy^pjATP and vanadate, auto¬
phosphorylation was reduced by 52% in the diabetic group (90). These
observations also emphasize the need to perform phosphorylation
measurements at multiple ATP concentrations, especially when using PM
preparations.
Lineweaver-Burke analysis also allowed the determination of the Km
of ATP for the insulin receptor tyrosine kinase. In both microsomal
(Figure 13) and PM (Figure 14) preparations, the Km's for ATP were
reduced in the diabetic groups in comparison to the control group.
Although the reduction in Km in diabetic preparations might have been
due to changes in the structure or conformation of the insulin receptor (no
changes have been observed [41]), reduced levels of ATPase/phosphatase
activities in the diabetic preparations are more likely to have been
responsible for the current observations. Indeed, the higher Km (ATP)
seen in the PM control preparation suggests that a greater degree of
vanadate-insensitive ATPases were present.
Lin (76) has described the presence of a calcium/magnesium ectoATPase in detergent solubilized preparations of rat hepatic PM. This
activity is not identical to membrane ion-pump ATPases based on
insensitivity to specific ion-pump ATPase inhibitors, such as vanadate, and
the lack of substrate specificity toward ATP. Although the function of this
ecto-ATPase is not known, Lin (76) suggested that it may function to
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regulate extracellular ATP levels. An ATPase/phosphatase activity was
found in this study in both PM and microsomal insulin receptor prepa¬
rations and found to be only partially suppressible in the former by 1 mM
vanadate. Further studies (90) have shown the presence of a nucleotide
hydrolyzing activity in PM preparations capable of utilizing GTP,
insensitive to vanadate (1 mM), EGTA, and ouabain, and dependent on
magnesium or calcium for activation.

Indeed, the ATP hydrolyzing activity

in the present study may be related to Lin's ecto-ATPase (76) and seems to
be altered by diabetes in some way that reduces its concentration and/or
activity.
The results of the present study and its continuation by this
laboratory (90) seem to suggest that a defect in insulin receptor function at
the level of the tyrosine kinase is present in diabetes and cannot be
explained by changes in ATPase/phosphatase activity.

In fact, more

ATPase/phosphatase activity was detected in the control preparations
implying that insulin receptor tyrosine kinase activity is reduced by
diabetes even more than observed in the present study because of the
presence of vanadate-insensitive ATPase/phosphatase activity. The present
study is the first to show that this reduction of tyrosine kinase activity by
diabetes is also present in PM insulin receptors.
The mechanism(s) underlying this alteration in insulin receptor
function by diabetes is unclear. One investigator (36) has suggested that
diabetes increased the Km (ATP) of the insulin receptor kinase, but the
results of the present study show the Km (ATP) to be reduced by diabetes.
Other studies have suggested that changes in phosphotyrosine phospha¬
tases are responsible, but the current and following (90) studies found
greater phosphatase activity in the control group. Structural or confor-
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mational changes in the insulin receptor secondary to alterations in
maturation or glycosylation have been suggested (36,40,41) hut not been
confirmed (40). There is some evidence (11,14,29,36) for a defective auto¬
activation cascade in the diabetic insulin receptor leading to inadequate
signal coupling. Another theory is that diabetes increases serine
phosphorylation of the insulin receptor causing it to become inactivated
(36,40,41,80). Further research is still needed to define the mechanism(s)
underlying the diabetes-induced alterations in the insulin receptor tyrosine
kinase before new methods of therapy and prevention can be developed for
this common and devastating disease.
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